There are currently 523 clinical trials in Tucson, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Arizona, Banner University Medical Center - Tucson, Arizona Cancer Center and University of Arizona Cancer Center-North Campus. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Arizona Oncology Associates, PC-Hope,1845 W Orange Grove Rd, Tucson, Arizona +3 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
NCT06388018
Recruiting
This phase II trial tests how well tailoring therapy in post-surgery works in patients with low-risk endometrial cancer. The usual approach for patients with low-risk endometrial cancer is treatment with surgery. In this study, tissue that is removed as part of the surgical procedure is analyzed in the pathology laboratory to help guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +2 locations
Conditions: Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC V8, Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC V8, Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC V8
Register for Updates
Intravesical Gem/Doce in Patients With NMIBC
NCT05644041
Recruiting
Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer (NMIBC) is a well-established treatment for preventing or delaying tumor recurrence after tumor resection. For high-risk non-muscle invasive bladder cancer, immunotherapy in the form of intravesical Bacillus Calmette-Guérin (BCG) can be effective as first-line; nevertheless, the response rate to BCG is suboptimal with many patients failing treatment. Following BCG-failure, however, very few effective therapeutic op... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Urinary Bladder Cancer
Register for Updates
A Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Research Site 111, Tucson, Arizona
Conditions: Advanced Solid Tumors
Register for Updates
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
NCT05318105
Recruiting
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Banner Health, Tucson, Arizona
Conditions: Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload
Register for Updates
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
NCT05121051
Recruiting
This phase II trial tests whether broccoli seed and sprout extract works to break down cancer causing substances of tobacco in heavy smokers. Smokers are at increased risk for developing lung, head and neck, and other cancers. Broccoli seed and sprout extract may help break down and remove toxic substances caused by tobacco use and possibly produce substances that may protect cells from tobacco smoke-induced damage in current smokers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona
Conditions: Cigarette Smoking-Related Carcinoma
Register for Updates
Optimizing Body Mass Index (BMI) With TCMCB07, The Paradox Trial
NCT06937177
Recruiting
This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 100 patients with newly diagnosed metastatic colorectal cancer. This study will evaluate different doses of B07 on weight, body composition and BMI in patients with sub-optimal BMIs (18 to ≤ 29 kg/m2). Treatment will begin on the same day as the start of cancer chemotherapy and continue during the first 28 days of cytotoxic therapy with a goal of preserving muscle and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Investigative Site, Tucson, Arizona
Conditions: Cachexia; Cancer
Register for Updates
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/07/2025
Locations: Center for Neurosciences, Tucson, Arizona
Conditions: Focal Epilepsy
Register for Updates
Project Talk Trial: Engaging Underserved Communities in End-of-life Conversations
NCT04612738
Recruiting
Compared to the general population, individuals from underserved communities are more likely to receive low quality end-of-life care and unwanted, costly and burdensome treatments due in part to a lack of advance care planning (ACP; the process of discussing wishes for end-of-life care with loved ones/clinicians and documenting them in advance directives). This study will use existing, trusted, and respected social networks to evaluate two conversation-based tools intended to engage underserved... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: El Rio Neighborhood Center, Tucson, Arizona
Conditions: Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
Register for Updates
Adaptive Symptom Self-Management Immunotherapy Study
NCT05715255
Recruiting
The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or severe symptoms to health care providers (HCPs) may reduce irAE severity by early recognition and management, resulting in fewer treatment interruptions and unscheduled health services.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Breast Cancer, Colon Cancer, Lung Cancer, Skin Cancer, Rectum Cancer
Register for Updates
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
NCT05831111
Recruiting
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/06/2025
Locations: Noble Clinical Research, Tucson, Arizona
Conditions: Epstein-Barr Virus Infection
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Pima Heart and Vascular Research Center, Tucson, Arizona +1 locations
Conditions: Heart Failure
Register for Updates